✦ LIBER ✦
Pr4 ISEL: A Phase III survival study comparing gefitinib (IRESSA) plus best supportive care (BSC) with placebo plus BSC, in patients with advanced non-small-cell lung cancer (NSCLC) who had received one or two prior chemotherapy regimens
✍ Scribed by Thatcher, N.; Chang, A.; Parikh, P.; Pemberton, K.; Archer, V.
- Book ID
- 118572546
- Publisher
- Elsevier Science
- Year
- 2005
- Tongue
- English
- Weight
- 138 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0169-5002
No coin nor oath required. For personal study only.